Steris (STE) Cash & Equivalents (2017 - 2026)

Steris' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $439.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 156.03% year-over-year to $439.6 million; the TTM figure through Mar 2026 stood at $439.6 million (up 156.03% YoY), while the FY2026 annual figure was $439.6 million, up 156.03% from the prior year.
• Cash & Equivalents was $439.6 million for Q1 2026 at Steris, up from $423.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $439.6 million in Q1 2026 to a low of $155.2 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $257.4 million across 5 years, with a median of $213.8 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents plunged 40.85% in 2022, then surged 173.04% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $259.4 million in 2022, then dropped by 24.59% to $195.6 million in 2023, then dropped by 20.66% to $155.2 million in 2024, then surged by 173.04% to $423.7 million in 2025, then climbed by 3.75% to $439.6 million in 2026.
• The last three Cash & Equivalents figures came in at $439.6 million (Q1 2026), $423.7 million (Q4 2025), and $319.2 million (Q3 2025), per Business Quant data.